Citations

Clear

79 citation(s) found for "Shang, Lu".

The applications of spinal cord stimulation in diseases with motor disorders, pain, and cognitive disturbance
Wen, Linxin, Zheng, Ruoyi , Cheng, Ruogu, Gao, Ye , Wen, Muzi, Shang, Pei , Wen, Linxin, Lin, Mingkai

Mayo Clinic

Advanced Technology in Neuroscience | November 7, 2024 | Volume: 1 | Issue: 1 | Pages: 2-17

10.4103/atn.atn-d-24-00001 Get It

Spinal cord stimulation (SCS), first used for pain relief in 1967, serves as an invasive neuromodulation with the targeted delivery of stimulations and the alertness of neural activities. Based on the gate-controlled theory of pain and multiple research studies, the application of SCS to motor recovery, pain relief, and sensory and cognitive restoration has been shown to be significant. Considering that movement disorders and pain are complications of various diseases, the categories, applications, and technical operation of SCS are coming of age. In terms of its impact on the immune system, SCS alters the trajectory of neurological diseases by modulating local immune responses through immunomodulatory mechanisms that vary depending on the different patterns of SCS. In addition to existing targets, the combinations of SCS and emerging techniques deepen the research at the molecular level, contributing to the exploration of potential targets and novel treatments. However, to secure a place in the future trend of non-invasive and precise treatment, it is necessary to improve SCS in terms of mechanism research, cost reduction, and application to more diseases.
Establishing Consensus for Mohs Micrographic Surgical Techniques in the Treatment of Melanoma in Situ for Future Clinical Trials: A Modified Delphi Study
Curtis, K., Fakult, Nathan J., Strunck, Jennifer L. , Aasi, Sumaira Z. , Ahn, Christine , Alam, Murad, Bar, Anna, Behshad, Ramona, Bichakjian, Christopher K. , Bolotin, Diana, Boone, Susan L., Brewer, Jerry D., Carr, David R. , Castillo, Jason R., Christensen, Sean R. , Clark, Melanie A., Collins, Lindsey K., Demer, Addison M. , Eisen, Daniel B. , Feng, Hao , Firoz, Bahar, Grekin, Roy C. , Hirshburg, Jason M., Holmes, Todd, Huang, Conway C. , Jennings, Thomas , Konda, Sailesh , Leitenberger, Justin J. , Lewin, Jesse M., Ng, Elise, Orengo, Ida, Samie, Faramarz H. , Saylor, Drew K. , Soleymani, Teo, Tate, Jesalyn A. , Vidal, Nahid Y. , Vij, Alok , Wysong, Ashley , Xu, Yaohui G. , Carroll, Bryan T. , Curtis, Kristen K., Bordeaux, Jeremy S. , Carr, David R., Carucci, John A. , Jiang, Shang I. Brian , Maher, Ian A. , Sharon, Victoria R. , Swetter, Susan M. , Beek, Marta J. Van , Yu, Wesley Y.

Mayo Clinic

Journal of the National Comprehensive Cancer Network | July 30, 2024 | Volume: 22 | Issue: 8 | Pages: No page available

10.6004/jnccn.2024.7036 | PMID 39079545 Get It

Background: Mohs micrographic surgery (MMS) is a promising treatment modality for melanoma in situ (MIS). However, variations in surgical technique limit the generalizability of existing data and may impede future study of MMS in clinical trials. Methods: A modified Delphi method was selected to establish consensus on optimal MMS techniques for treating MIS in future clinical trials. The Delphi method was selected due to the limited current data, the wide range of techniques used in the field, and the intention to establish a standardized technique for future clinical trials. A literature review and interviews with experienced MMS surgeons were performed to identify dimensions of the MMS technique for MIS that (1) likely impacted costs or outcomes of the procedure, and (2) showed significant variability between surgeons. A total of 8 dimensions of technical variation were selected. The Delphi process consisted of 2 rounds of voting and commentary, during which 44 expert Mohs surgeons across the United States rated their agreement with specific recommendations using a Likert scale. Results: Five of eight recommendations achieved consensus in Round 1. All 3 of the remaining recommendations achieved consensus in Round 2. Techniques achieving consensus in Round 1 included the use of a starting peripheral margin of ≤5 mm, application of immunohistochemistry, frozen tissue processing, and resecting to the depth of subcutaneous fat. Consensus on the use of Wood’s lamp, dermatoscope, and negative tissue controls was established in Round 2. Conclusions: This study generated 8 consensus recommendations intended to offer guidance for Mohs surgeons treating MIS. The adoption of these recommendations will promote standardization to facilitate comparisons of aggregate data in multicenter clinical trials.
An open‐label, first‐in‐human, single agent, dose escalation study for the evaluation of safety and efficacy of SAR442085 in patients with relapsed or refractory multiple myeloma
Kapoor, Prashant , Pour, Luděk , Lichtman, Eben I. , Mateos, María‐Victoria , Kanagavel, Dheepak , Zhao, Liang , Guillemin‐Paveau, Hélène, Macé, Sandrine , Velde, Helgi van de , Richardson, Paul G. , Dimopoulos, Meletios A , Richardson, Paul Gerard Guy , Nathwani, Nitya , Jelı́nek, Tomáš , Perrot, Aurore , Dimopoulos, Meletios Α. , Huang, Shang‐Yi , Špıčka, Ivan , Chhabra, Saurabh

Mayo Clinic

European Journal of Haematology | July 12, 2024 | Volume: 113 | Issue: 5 | Pages: 593-605

10.1111/ejh.14270 | PMID 38993150 Get It

AbstractObjectivesCluster of differentiation 38 (CD38) is a key target on multiple myeloma (MM) cells. This multi‐centre, Phase 1, single‐agent study (NCT04000282) investigated SAR442085, a novel fragment crystallisable (Fc)‐modified anti‐CD38 monoclonal antibody (mAb), with enhanced affinity towards Fc‐gamma receptor on effector cells in patients with relapsed and/or refractory (RR) MM.MethodsThis study comprised two parts: Part‐A (dose‐escalation involving anti‐CD38 mAb pre‐treated and naïve patients) and Part‐B (dose expansion). Primary endpoints were maximum tolerated dose and recommended Phase 2 dose (RP2D).ResultsThirty‐seven heavily pre‐treated patients were treated in Part A. Part‐B (dose‐expansion) was not studied. Seven dose‐limiting toxicities were reported at DL3, DL5, DL6, and DL7. RP2D was determined to be 5–7·5 mg/kg. Most common treatment‐emergent adverse events were infusion‐related reactions in 70·3% (26/37) patients. Grade ≥3 thrombocytopenia was reported in 48·6% (18/37). Overall response rate was 70% in anti‐CD38 mAb naïve and 4% in anti‐CD38 pre‐treated patients, with a median progression‐free survival of 7·62 (95%CI: 2·858; not calculable) months and 2·79 (95%CI: 1·150; 4·172) months and, respectively.ConclusionsThe efficacy of SAR442085 was promising in anti‐CD38 mAb naïve patients but did not extend to the larger cohort of anti‐CD38 mAb pre‐treated patients. This observation, along with transient high‐grade thrombocytopenia, could potentially limit its clinical use.
Identification of biomarkers of Alzheimer's disease and their characterization of immune function
Zhou, Yue , Liang, Peixian , Zheng, Ruoyi , Du, Minwei, Ke, Xintong , Zhang, Wenjing , Shang, Pei , Shang, Pei , Lin, Mingkai , Liang, Peixian

Mayo Clinic

Archives of Medical Science | June 6, 2024 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.5114/aoms/188721 | PMID 40190307 Get It

IntroductionAlzheimer's disease (AD) is a neurodegenerative disease with neurogenic fiber tangles caused by amyloid-β protein plaques and tau protein hyperphosphorylation as the pathological manifestations. This study was based on multi-omics to investigate the mechanisms and immune characterization of AD.Material and methodsBased on bulk RNA-seq (GSE122063 and GSE97760), we screened potential biomarkers for AD by differential expression analysis and machine learning algorithms. Then, we elaborated the expression characteristics and immune functions of the above biomarkers by scRNA-seq (single-cell RNA sequencing) data analysis (GSM4996463 and GSM4996462) and immune infiltration analysis.ResultsFive biomarkers (RBM3, GOLGA8A, ALS2, FSD2, and LOC100287628) were identified using machine learning algorithms. Single-cell analysis revealed distinct expression patterns of these biomarkers in astrocytes from AD samples compared to normal samples. Additionally, three key biomarkers were selected based on interaction networks, and the diagnostic models indicated high diagnostic efficacy for these biomarkers. Based on immune infiltration and correlation analyses, RBM3, GOLGA8A, and ALS2 were all highly correlated with CD8 T cell content in the immune microenvironment of AD.ConclusionsThe biomarkers identified in this study demonstrate significant diagnostic potential for AD. Notably, the downregulation of RBM3 in astrocytes and the decreased presence of CD8 T cells infiltrating brain tissue are potential risk factors for AD.
Telisotuzumab Vedotin Monotherapy in Patients With Previously Treated c-Met Protein–Overexpressing Advanced Nonsquamous EGFR -Wildtype Non–Small Cell Lung Cancer in the Phase II LUMINOSITY Trial
Camidge, D. Ross , Bar, Jair , Goldman, Jonathan W. , Moiseenko, Fedor , Филиппова, Е. А. , Çiçin, İrfan , Daaboul, Nathalie , Liu, Chunling , Bradbury, Penelope A., Moskovitz, Mor, Katgı, Nuran , Cuppens, Kristof , Wu, Shang‐Yin , Baijal, Shobhit , Kuo, Chih‐Hsi S. , Planchard, David , Baik, Christina S. , Li, Martha, Ansell, Peter , Xia, Summer, Bolotin, Ellen, Looman, Jim, Ratajczak, Christine K. , Horinouchi, Hidehito , Goldman, Jonathan W , Moiseenko, Fedor , Cicin, Irfan , Zer Kuch, Alona , Girard, Nicolas , Cuppens, Kristof , Han, Ji-Youn , Wu, Shang-Yin , Mansfield, Aaron S , Kuo, Chih-Hsi , Nishino, Kazumi , Lee, Se-Hoon , Planchard, David , Lu, Shun , Filippova, Elena, Ciuleanu, Tudor–Eliade , Tomasini, Pascale , Girard, Nicolas , Mansfield, Aaron S.

Mayo Clinic

Journal of Clinical Oncology | June 6, 2024 | Volume: 42 | Issue: 25 | Pages: 3000-3011

10.1200/jco.24.00720 | PMID 38843488 Get It

PURPOSE Telisotuzumab vedotin (Teliso-V) is a c-Met–directed antibody-drug conjugate with a monomethyl auristatin E cytotoxic payload. The phase II LUMINOSITY trial (ClinicalTrials.gov identifier: NCT03539536 ) aimed to identify the optimal c-Met protein–overexpressing non–small cell lung cancer (NSCLC) population for treatment with Teliso-V (stage I) and expand the selected group for efficacy evaluation (stage II). Stage II enrolled patients with nonsquamous epidermal growth factor receptor ( EGFR )-wildtype NSCLC. METHODS Eligible patients had locally advanced/metastatic c-Met protein–overexpressing NSCLC and ≤2 previous lines of therapy (including ≤1 line of systemic chemotherapy). c-Met protein overexpression in nonsquamous EGFR -wildtype NSCLC was defined as ≥25% tumor cells with 3+ staining (high [≥50% 3+]; intermediate [≥25%–<50%]). Teliso-V was administered at 1.9 mg/kg once every 2 weeks. The primary end point was overall response rate (ORR) by independent central review. RESULTS In total, 172 patients with nonsquamous EGFR -wildtype NSCLC received Teliso-V in stages I and II. ORR was 28.6% (95% CI, 21.7 to 36.2; c-Met high, 34.6% [95% CI, 24.2 to 46.2]; c-Met intermediate, 22.9% [95% CI, 14.4 to 33.4]). The median duration of response was 8.3 months (95% CI, 5.6 to 11.3; c-Met high, 9.0 [95% CI, 4.2 to 13.0]; c-Met intermediate: 7.2 [95% CI, 5.3 to 11.5]). The median overall survival was 14.5 months (95% CI, 9.9 to 16.6; c-Met high, 14.6 [95% CI, 9.2 to 25.6]; c-Met intermediate, 14.2 [95% CI, 9.6 to 16.6]). The median progression-free survival was 5.7 months (95% CI, 4.6 to 6.9; c-Met high, 5.5 [95% CI, 4.1 to 8.3]; c-Met intermediate: 6.0 [95% CI, 4.5 to 8.1]). Most common any-grade treatment-related adverse events (AEs) were peripheral sensory neuropathy (30%), peripheral edema (16%), and fatigue (14%); the most common grade ≥3 AE was peripheral sensory neuropathy (7%). CONCLUSION Teliso-V was associated with durable responses in c-Met protein–overexpressing nonsquamous EGFR -wildtype NSCLC, especially in those with high c-Met. AEs were generally manageable.
New Insights on Mechanisms and Therapeutic Targets of Cerebral Edema
Zheng, Ruoyi , Wu, Kou, Yuan, Chao , Shang, Pei , Pan, Suyue

Mayo Clinic

Current Neuropharmacology | May 29, 2024 | Volume: 22 | Issue: 14 | Pages: 2330-2352

10.2174/1570159x22666240528160237 | PMID 38808718 Get It

: Cerebral Edema (CE) is the final common pathway of brain death. In severe neurological disease, neuronal cell damage first contributes to tissue edema, and then Increased Intracranial Pressure (ICP) occurs, which results in diminishing cerebral perfusion pressure. In turn, anoxic brain injury brought on by decreased cerebral perfusion pressure eventually results in neuronal cell impairment, creating a vicious cycle. Traditionally, CE is understood to be tightly linked to elevated ICP, which ultimately generates cerebral hernia and is therefore regarded as a risk factor for mortality. Intracranial hypertension and brain edema are two serious neurological disorders that are commonly treated with mannitol. However, mannitol usage should be monitored since inappropriate utilization of the substance could conversely have negative effects on CE patients. CE is thought to be related to bloodbrain barrier dysfunction. Nonetheless, a fluid clearance mechanism called the glial-lymphatic or glymphatic system was updated. This pathway facilitates the transport of cerebrospinal fluid (CSF) into the brain along arterial perivascular spaces and later into the brain interstitium. After removing solutes from the neuropil into meningeal and cervical lymphatic drainage arteries, the route then directs flows into the venous perivascular and perineuronal regions. Remarkably, the dual function of the glymphatic system was observed to protect the brain from further exacerbated damage. From our point of view, future studies ought to concentrate on the management of CE based on numerous targets of the updated glymphatic system. Further clinical trials are encouraged to apply these agents to the clinic as soon as possible.
Single-cell analysis of anti-BCMA CAR T cell therapy in patients with central nervous system autoimmunity
Qin, Chuan , Zhang, Min , Mou, Dapeng , Zhou, Luo‐Qi , Dong, Ming‐Hao , Huang, Liang , Wang, Wen , Cai, Song-Bai , You, Yun‐Fan , Shang, Ke , Xiao, Jun , Wang, Di , Li, Chunrui , Hao, Yi , Wu, Long‐Jun , Bu, Bi-Tao, Wang, Wei , Li, Chun-Rui , Heming, Michael , Wu, Long-Jun , Meyer Zu Hörste, Gerd , Dong, Chen , Bu, Bi-Tao , Tian, Dai-Shi , Wang, Wei , Wang, Wen , Tian, Dai‐Shi

Mayo Clinic

Science Immunology | May 10, 2024 | Volume: 9 | Issue: 95 | Pages: No page available

10.1126/sciimmunol.adj9730 | PMID 38728414 Get It

Chimeric antigen receptor (CAR) T cell immunotherapy for the treatment of neurological autoimmune diseases is promising, but CAR T cell kinetics and immune alterations after treatment are poorly understood. Here, we performed single-cell multi-omics sequencing of paired cerebrospinal fluid (CSF) and blood samples from patients with neuromyelitis optica spectrum disorder (NMOSD) treated with anti–B cell maturation antigen (BCMA) CAR T cells. Proliferating cytotoxic-like CD8 + CAR T cell clones were identified as the main effectors in autoimmunity. Anti-BCMA CAR T cells with enhanced features of chemotaxis efficiently crossed the blood-CSF barrier, eliminated plasmablasts and plasma cells in the CSF, and suppressed neuroinflammation. The CD44-expressing early memory phenotype in infusion products was potentially associated with CAR T cell persistence in autoimmunity. Moreover, CAR T cells from patients with NMOSD displayed distinctive features of suppressed cytotoxicity compared with those from hematological malignancies. Thus, we provide mechanistic insights into CAR T cell function in patients with neurological autoimmune disease.
Long-term efficacy and safety of eculizumab monotherapy in AQP4+ neuromyelitis optica spectrum disorder (1578)
Kim, Ho Jin , Guevara, Celia Oreja, Shang, Shulian, Yountz, Marcus, Miller, Larisa , Armstrong, Róisín, Wingerchuk, Dean M. , Pittock, Sean J. , Fujihara, Kazuo , Palace, Jacqueline , Berthele, Achim , Nakashima, Ichiro , Levy, Michael

Mayo Clinic

Neurology | December 7, 2023 | Volume: 96 | Issue: 15_supplement | Pages: No page available

10.1212/wnl.96.15_supplement.1578 Get It

Impact of Eculizumab on Health Outcomes in Patients with Aquaporin-4 Antibody-Positive Neuromyelitis Optica Spectrum Disorder: Findings from the PREVENT Study (1765)
Kim, Ho Jin , Palace, Jacqueline , Terzi, Murat , Wang, Kaichen , Shang, Shulian, Yountz, Marcus, Armstrong, Róisín, Wingerchuk, Dean M. , Palace, Jacqueline , Berthele, Achim , Pittock, Sean J. , Fujihara, Kazuo , Levy, Michael , Nakashima, Ichiro , Totolyan, N. А. , Viswanathan, Shanthi

Mayo Clinic

Neurology | December 7, 2023 | Volume: 94 | Issue: 15_supplement | Pages: No page available

10.1212/wnl.94.15_supplement.1765 Get It

Impact of Eculizumab on Disability Worsening and Quality of Life in Patients with Aquaporin-4 Antibody-Positive Neuromyelitis Optica Spectrum Disorder: Results from the Phase 3 PREVENT Study (1658)
Kim, Ho Jin , Terzi, Murat , Wang, Kaichen , Shang, Shulian, Yountz, Marcus, Armstrong, Róisín, Wingerchuk, Dean M. , Palace, Jacqueline , Pittock, Sean J. , Berthele, Achim , Fujihara, Kazuo , Levy, Michael , Nakashima, Ichiro , Totolyan, N. А. , Viswanathan, Shanthi

Mayo Clinic

Neurology | December 7, 2023 | Volume: 94 | Issue: 15_supplement | Pages: No page available

10.1212/wnl.94.15_supplement.1658 Get It